Compliance to treatment guidelines and survival in women undergoing interval debulking surgery for advanced epithelial ovarian cancer

被引:2
|
作者
Shylasree, Thumkur S. [1 ]
Kattepur, Abhay K. [1 ]
Gupta, Monisha [1 ]
Ghosh, Jaya [2 ]
Maheshwari, Amita [1 ]
Bajpai, Jyoti [2 ]
Hawaldar, Rohini [3 ]
Gulia, Seema [2 ]
Deodhar, Kedar [4 ]
Popat, Palak [5 ]
Gupta, Sudeep [2 ]
Kerkar, Rajendra A. [1 ]
机构
[1] Tata Mem Hosp, Dept Gynecol Oncol, Mumbai, Maharashtra, India
[2] Tata Mem Hosp, Dept Med Oncol, Mumbai, Maharashtra, India
[3] Tata Mem Hosp, Dept Clin Res Methodol & Biostat, Mumbai, Maharashtra, India
[4] Tata Mem Hosp, Dept Pathol, Mumbai, Maharashtra, India
[5] Tata Mem Hosp, Dept Radiodiag, Mumbai, Maharashtra, India
关键词
advanced epithelial ovarian cancer; compliance; deviation; interval debulking surgery; survival; NEOADJUVANT CHEMOTHERAPY; CLINICAL-OUTCOMES; ADHERENCE;
D O I
10.1002/cnr2.1217
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundOne of the primary treatment strategies for advanced epithelial ovarian cancers includes neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) and adjuvant chemotherapy. Compliance to treatment is important to possibly improve outcomes. AimTo audit treatment compliance and its effect on overall survival (OS) and disease free survival (DFS) in women undergoing IDS. Methods and ResultsWomen diagnosed with advanced epithelial ovarian cancer undergoing IDS were included. Details of compliance to chemotherapy and surgery as per standard guidelines were assessed, and correlation with survival was studied. Reasons for protocol deviation at various levels were documented and analysed. A total of 182 patients were included. The total number of deviations was 134 with deviation at any level being 89 (48.9%) and at all levels 5%. Both patient- and treatment-related factors contributed towards deviation. Deviation or noncompliance towards treatment resulted in a significantly reduced 5-year OS (34.4% vs 58.2%; P = .001) compared with compliant patients, which retained its significance on multivariate analysis (P = .024) as well. ConclusionDeviation from treatment guidelines resulted in a significantly lower 5-year OS compared with those who remained treatment compliant. Both patient- and treatment-related factors contributed towards noncompliance and hence towards lower survival.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer
    Morice, P
    Dubernard, G
    Rey, A
    Atallah, D
    Pautier, P
    Pomel, C
    Lhommé, C
    Duvillard, P
    Castaigne, D
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2003, 197 (06) : 955 - 963
  • [22] NEOADJUVANT CHEMOTHERAPY AND INTERVAL DEBULKING FOR ADVANCED EPITHELIAL OVARIAN-CANCER
    JACOB, JH
    GERSHENSON, DM
    MORRIS, M
    COPELAND, LJ
    BURKE, TW
    WHARTON, JT
    GYNECOLOGIC ONCOLOGY, 1991, 42 (02) : 146 - 150
  • [23] INTERVENTION DEBULKING SURGERY IN ADVANCED EPITHELIAL OVARIAN-CANCER
    REDMAN, CWE
    WARWICK, J
    LUESLEY, DM
    VARMA, R
    LAWTON, FG
    BLACKLEDGE, GRP
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1994, 101 (02): : 142 - 146
  • [24] Rethinking of radical surgery at interval debulking surgery for advanced-stage ovarian cancer undergoing neoadjvuant chemotherapy
    Lee, Y. J.
    Lee, J. Y.
    Nam, E. J.
    Kim, S. W.
    Kim, S.
    Kim, Y. T.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 85 - 85
  • [25] Neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer - a retrospective cohort study
    Maricic, Slobodan
    Mandic, Aljosa
    Dejanovic, Ninoslav
    Kladar, Nebojsa
    Popovic, Marina
    Ivkovic-Kapicl, Tatjana
    Gutic, Bojana
    Kokanov, Dunja
    VOJNOSANITETSKI PREGLED, 2021, 78 (11) : 1193 - 1199
  • [26] Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer
    Makar, Amin P.
    Trope, Claes G.
    Tummers, Philippe
    Denys, Hannelore
    Vandecasteele, Katrien
    ONCOLOGIST, 2016, 21 (06): : 745 - 754
  • [27] Difference in hemodynamic parameters in patients (PTS) with advanced epithelial ovarian cancer (EOC) undergoing primary (PDS) or interval debulking surgery (IDS)
    Bommert, Mareike
    Mospanov, Wlad
    Stiegler, Viviane
    Groeben, Harald
    Traut, Alexander
    Heitz, Florian
    Schneider, Stephanie
    Moubarak, Malak
    Welz, Julia
    Vrentas, Vasileios
    Harter, Philipp
    Feldheiser, Aarne
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A170 - A171
  • [28] Optimal Debulking Targets in Women With Advanced Stage Ovarian Cancer: A Retrospective Study of Immediate Versus Interval Debulking Surgery
    Altman, Alon D.
    Nelson, Gregg
    Chu, Pamela
    Nation, Jill
    Ghatage, Prafull
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2012, 34 (06) : 558 - 566
  • [29] Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Hong Zheng
    Yu-Nong Gao
    ChineseJournalofCancerResearch, 2012, 24 (04) : 304 - 309
  • [30] Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Zheng, Hong
    Gao, Yu-Nong
    CHINESE JOURNAL OF CANCER RESEARCH, 2012, 24 (04) : 304 - 309